mhurhangee/ep-ind-claims huggingface dataset:
A dicing die bonding film, comprising: a die bonding portion having an adhesive layer adhering to a wafer; and a dicing portion having a tacky layer, wherein a ratio X/Y of adhesive power X between the wafer and the adhesive layer of the die bonding portion to tacky power Y between the die bonding portion and the tacky layer of the dicing portion is 0.15 to 1, and the adhesive layer of the die bonding portion has a storage modulus of 100 to 1000 MPa at a normal temperature, and wherein. the adhesive layer of the die bonding portion includes a) thermosetting multi-functional epoxy resin; and b) low elasticity high molecular resin. a die bonding portion having an adhesive layer adhering to a wafer; and a dicing portion having a tacky layer, wherein a ratio X/Y of adhesive power X between the wafer and the adhesive layer of the die bonding portion to tacky power Y between the die bonding portion and the tacky layer of the dicing portion is 0.15 to 1, and the adhesive layer of the die bonding portion has a storage modulus of 100 to 1000 MPa at a normal temperature, and wherein. the adhesive layer of the die bonding portion includes a) thermosetting multi-functional epoxy resin; and b) low elasticity high molecular resin.
A genetically modified mouse, comprising: a. a mouse RAG gene knockout; b. a mouse II2rg gene knockout; c. a replacement of a mouse IL-3 gene with a human IL-3 gene, wherein the human IL-3 gene is at a mouse IL-3 gene locus; d. a replacement of a mouse GM-CSF gene with a human GM-CSF gene, wherein the human GM-CSF gene is at a mouse GM-CSF gene locus; e. an engraftment of human hematopoietic stem and progenitor cells (HSPC); and f. an infection by a human pathogen; and substantially lacking endogenous mouse hematopoietic cells. a. a mouse RAG gene knockout; b. a mouse II2rg gene knockout; c. a replacement of a mouse IL-3 gene with a human IL-3 gene, wherein the human IL-3 gene is at a mouse IL-3 gene locus; d. a replacement of a mouse GM-CSF gene with a human GM-CSF gene, wherein the human GM-CSF gene is at a mouse GM-CSF gene locus; e. an engraftment of human hematopoietic stem and progenitor cells (HSPC); and f. an infection by a human pathogen;
An assembly for use in fixing a tibial component of a knee prosthesis to a prepared tibia, the assembly comprising: (a) a tibial component of knee prosthesis having a bone facing surface for fixing on to a patient's tibia and an exposed surface which faces towards the femoral component of the knee prosthesis when the tibial component is implanted on a patient's tibia, and (b) a skirt (1, 22) which can be temporarily fixed to the edge of the tibial component extending along the edge thereof from a remote posterior portion of the edge to an accessible anterior portion of the edge, characterised in that the skirt has a break off portion which can be broken off to provide at least one opening in the skirt on the anterior portion of the edge of the tibial component, through which cement located in contact with the bone facing surface of the component can be displaced when the tibial component is placed on a patient's tibia and force is applied to the component in a direction towards the tibia, the skirt preventing displacement of cement from the space between the bone facing surface of the component and the tibia at the remote posterior portion of the edge. (a) a tibial component of knee prosthesis having a bone facing surface for fixing on to a patient's tibia and an exposed surface which faces towards the femoral component of the knee prosthesis when the tibial component is implanted on a patient's tibia, and (b) a skirt (1, 22) which can be temporarily fixed to the edge of the tibial component extending along the edge thereof from a remote posterior portion of the edge to an accessible anterior portion of the edge, characterised in that the skirt has a break off portion which can be broken off to provide at least one opening in the skirt on the anterior portion of the edge of the tibial component, through which cement located in contact with the bone facing surface of the component can be displaced when the tibial component is placed on a patient's tibia and force is applied to the component in a direction towards the tibia, the skirt preventing displacement of cement from the space between the bone facing surface of the component and the tibia at the remote posterior portion of the edge.
A powdered creamer composition comprising: - 1-8% by weight of plant protein; - 12-50% by weight of vegetable oil; - 25-80 % by weight of carbohydrate; - 0.5-5% by weight of sodium bicarbonate; - 0.2-3% by weight of citric acid; and wherein the plant protein has a median molecular weight comprised in the range of between 800 and 20,000 Daltons. - 1-8% by weight of plant protein; - 12-50% by weight of vegetable oil; - 25-80 % by weight of carbohydrate; - 0.5-5% by weight of sodium bicarbonate; - 0.2-3% by weight of citric acid; and
A method for sensitive identification of high-affinity complexes made of two ligands (2, 3, 4, 5, 6, 7) and one receptor, comprising the steps i) interaction of a large number of different complexes made of ligands (2, 3, 4, 5, 6, 7) of a chemical library with at least one receptor in a solution, the ligands (2, 3, 4, 5, 6, 7) of the library having a single-strand DNA (8, 9) or RNA with a base length of more than 2 bases, which is bonded chemically covalently to the ligands (2, 3, 4, 5, 6, 7), and only 2 to 10 bases of the single-strand DNA or RNA of a first part of the ligands (2, 6, 7) being complementary to bases of the single-strand DNA or RNA of a second part of the ligands (3, 4, 5); ii) incubation of the solution for a specific period of time, complexes made of ligand complexes and the receptor being produced; iii) identification of the resulting complexes made of ligand complexes and the receptor, characterized in that the solution is incubated at a room temperature at which, between the first part of the ligands (2, 6, 7) and the second part of the ligands (3, 4, 5), an equilibrium of hybridisation to form ligand complexes and dissociation to form free ligands (2, 3, 4, 5, 6, 7) arises, wherein, in step i), the ligands are complexed to form ligand complexes via hybridisation of the DNA (8, 9) or RNA, wherein the single-strand DNA or RNA in the first part of the ligands (2, 6, 7) and the single-strand DNA or RNA in the second part of the ligands (3, 4, 5) comprises a base sequence which codes for the chemically covalently-bonded ligand (2, 3, 4, 5, 6, 7). i) interaction of a large number of different complexes made of ligands (2, 3, 4, 5, 6, 7) of a chemical library with at least one receptor in a solution, the ligands (2, 3, 4, 5, 6, 7) of the library having a single-strand DNA (8, 9) or RNA with a base length of more than 2 bases, which is bonded chemically covalently to the ligands (2, 3, 4, 5, 6, 7), and only 2 to 10 bases of the single-strand DNA or RNA of a first part of the ligands (2, 6, 7) being complementary to bases of the single-strand DNA or RNA of a second part of the ligands (3, 4, 5); ii) incubation of the solution for a specific period of time, complexes made of ligand complexes and the receptor being produced; iii) identification of the resulting complexes made of ligand complexes and the receptor,
Vulcanizable rubber mixture with at least one rubber polymer, one or more fillers and optionally additives, characterized in that the rubber fraction comprises from 1 to 100% by weight of a conjugated diolefin-styrene copolymer with from 10 to 60 mol% styrene content, characterized in that the distribution of the styrene units and of the conjugated diene units along the chain exhibits a gradient produced by variation of the monomer concentrations of diolefin and styrene during the polymerization reaction, so that the maximal value for tan δ determined from the dynamic mechanical analysis data, measured as in the description, for the pure SBR polymer (in accordance with DIN 53513) occurs at a temperature at least 30°C higher than that of the first maximum of the loss modulus in the direction of rising temperature values (in accordance with DIN 53 513).
A feeding apparatus comprising: a container having an open end and for defining a main chamber therein upon assembly of the apparatus; a flexible mouthpiece for assembly to the open end of the container and for defining a secondary chamber therein upon assembly of the apparatus; characterised in that the feeding apparatus further comprises: a cartridge comprising a base section for locating within the open end of the container upon assembly of the apparatus, a partition for separating the main and secondary chambers in the assembled apparatus and biasing means to bias the partition away from the base section and into contact with a deformable flap of mouthpiece material in the assembled apparatus; wherein in the assembled apparatus the contact between the deformable flap of mouthpiece material and the partition forms a one-way valve to restrict the flow of liquid feed from the secondary chamber to the main chamber but to permit the flow of liquid feed from the main chamber to the secondary chamber during feeding; and wherein the mouthpiece includes a protruding teat provided at a feeding end with a self-closing valve. a container having an open end and for defining a main chamber therein upon assembly of the apparatus; a flexible mouthpiece for assembly to the open end of the container and for defining a secondary chamber therein upon assembly of the apparatus; characterised in that the feeding apparatus further comprises: a cartridge comprising a base section for locating within the open end of the container upon assembly of the apparatus, a partition for separating the main and secondary chambers in the assembled apparatus and biasing means to bias the partition away from the base section and into contact with a deformable flap of mouthpiece material in the assembled apparatus; wherein in the assembled apparatus the contact between the deformable flap of mouthpiece material and the partition forms a one-way valve to restrict the flow of liquid feed from the secondary chamber to the main chamber but to permit the flow of liquid feed from the main chamber to the secondary chamber during feeding; and wherein the mouthpiece includes a protruding teat provided at a feeding end with a self-closing valve. a cartridge comprising a base section for locating within the open end of the container upon assembly of the apparatus, a partition for separating the main and secondary chambers in the assembled apparatus and biasing means to bias the partition away from the base section and into contact with a deformable flap of mouthpiece material in the assembled apparatus; wherein in the assembled apparatus the contact between the deformable flap of mouthpiece material and the partition forms a one-way valve to restrict the flow of liquid feed from the secondary chamber to the main chamber but to permit the flow of liquid feed from the main chamber to the secondary chamber during feeding; and wherein the mouthpiece includes a protruding teat provided at a feeding end with a self-closing valve.
An electronic device for seamlessly authenticating a user, the electronic device comprising: a touch-sensitive display; a fingerprint sensor; means for displaying a graphical element on the touch-sensitive display, characterised in that: the graphical element is configured to indicate a first direction of movement of a finger on the touch sensitive display such that the finger is moved over the fingerprint sensor, wherein the fingerprint sensor is configured to authenticate the user as the finger is moved over the fingerprint sensor. a touch-sensitive display; a fingerprint sensor; means for displaying a graphical element on the touch-sensitive display, characterised in that: the graphical element is configured to indicate a first direction of movement of a finger on the touch sensitive display such that the finger is moved over the fingerprint sensor, wherein the fingerprint sensor is configured to authenticate the user as the finger is moved over the fingerprint sensor. the graphical element is configured to indicate a first direction of movement of a finger on the touch sensitive display such that the finger is moved over the fingerprint sensor, wherein the fingerprint sensor is configured to authenticate the user as the finger is moved over the fingerprint sensor.
Device for processing food arranged in a cooking vessel (50a, 50b), said device comprising means for fastening (3, 4) on said cooking vessel (50a, 50b) which allow for a coupling/decoupling of said device on the cooking vessel (50a, 50b) and a drive shaft of a rotating tool intended to engage with said food, the tool being transversally mobile to a vertical axis of extension of the drive shaft between first and second working positions, the rotating tool comprising at least first and second housings (41, 42) for receiving the drive shaft which are arranged side by side, the tool being in the first working position when the drive shaft is arranged in the first housing and the tool being in the second working position when the drive shaft is arranged in the second housing and the tool being immobilised on the drive shaft by retaining means (28, 39) that allow for a mounting/dismounting of the tool with respect to the drive shaft without tools, characterised in that the drive shaft comprises a first portion of which the transversal section has a non-circular shape, with each housing (41, 42) extending along the vertical axis and having a transversal section of a shape that is complementary with the non-circular shape.
A terminal, comprising a processor and a touch control button, wherein the touch control button comprises a touch control sensor and a button cover plate; the processor is electrically connected to the touch control sensor; the button cover plate is located above a sensor sheet of the touch control sensor; the processor is configured to acquire a detecting signal value of the touch control sensor, to determine a control instruction corresponding to the detecting signal value according to pre-stored corresponding relationships between detecting signal values and control instructions, and to execute the control instruction, wherein the detecting signal value of the touch control sensor increases with an increase of a sensing area of the sensor sheet, and a function of the touch control button varies with the sensing area of the sensor sheet; wherein the terminal comprises one touch control button; wherein the touch control sensor comprises at least two sensor sheets, and the detecting signal value of the touch control sensor comprises detecting signal values corresponding respectively to the at least two sensor sheets; wherein the at least two sensor sheets are located on a same plane and are arranged in a surrounded structure from inside to outside, and are separated with each other; and wherein the touch control sensor comprises a preset number of sensor sheets; the processor is configured to acquire the detecting signal value corresponding to each sensor sheet of the touch control sensor, to determine a number of continuously distributed sensor sheets beginning from an innermost sensor sheet in a surrounded structure and having corresponding detecting signal values larger than a pre-set threshold, and to determine the control instruction corresponding to a number range the number falls into according to pre-stored corresponding relationships between number ranges and control instructions, and to execute the control instruction.
A pharmaceutical formulation characterized in that it comprises: at least one active pharmaceutical ingredient having low aqueous solubility or a pharmaceutically acceptable salt thereof in the form of particles of a size between 1 and 800 nm, wherein said particles are encapsulated within a large microparticle of a size between 1 and 100 μm formed by a matrix comprising at least an excipient, wherein the active pharmaceutical ingredient having low aqueous solubility is selected from the group of Biopharmaceutical Classification System classes II and IV, wherein the microparticles of a size between 1 and 100 μm encapsulating particles of a size between 1 and 800 nm are prepared by the process described in any of claims 10 to 12 and wherein each microparticle encapsulating the API or a pharmaceutically acceptable salt thereof comprises between 20-85% by weight of the API or a pharmaceutically acceptable salt thereof and between 15-80% by weight of one or more excipients and wherein the pharmaceutical formulation comprises: a) 10-85% by weight of microparticles encapsulating the API or a pharmaceutically acceptable salt thereof; b) 15-90% by weight of additional excipients. at least one active pharmaceutical ingredient having low aqueous solubility or a pharmaceutically acceptable salt thereof in the form of particles of a size between 1 and 800 nm, wherein said particles are encapsulated within a large microparticle of a size between 1 and 100 μm formed by a matrix comprising at least an excipient, wherein the active pharmaceutical ingredient having low aqueous solubility is selected from the group of Biopharmaceutical Classification System classes II and IV, wherein the microparticles of a size between 1 and 100 μm encapsulating particles of a size between 1 and 800 nm are prepared by the process described in any of claims 10 to 12 and wherein each microparticle encapsulating the API or a pharmaceutically acceptable salt thereof comprises between 20-85% by weight of the API or a pharmaceutically acceptable salt thereof and between 15-80% by weight of one or more excipients and wherein the pharmaceutical formulation comprises: a) 10-85% by weight of microparticles encapsulating the API or a pharmaceutically acceptable salt thereof; b) 15-90% by weight of additional excipients. a) 10-85% by weight of microparticles encapsulating the API or a pharmaceutically acceptable salt thereof; b) 15-90% by weight of additional excipients.
A method for printing on a substrate comprising two steps; the first step consists essentially of: applying onto a substrate one or more layers of an energy curable ink and applying one or more layers of a water-based coating over the top of the one or more layers of energy curable ink; the second step comprises the steps of: a) drying the one or more layers of water-based coating, and b) actinically or electron beam curing simultaneously all the energy curable ink layers the first step consists essentially of: applying onto a substrate one or more layers of an energy curable ink and applying one or more layers of a water-based coating over the top of the one or more layers of energy curable ink; the second step comprises the steps of: a) drying the one or more layers of water-based coating, and b) actinically or electron beam curing simultaneously all the energy curable ink layers a) drying the one or more layers of water-based coating, and b) actinically or electron beam curing simultaneously all the energy curable ink layers
Wood stove air regulator comprising at least one valve, such as three valves (19', 19", 19′′′) and with a housing configured for fitting into a wood stove and configured for receiving control signals from a burn controller, wherein the valve is a cylindrical valve with a valve piston and actuation means for linearly positioning the valve piston relatively to a valve port frame for controlling the flow of combustion air through a valve port, characterised in that said valve port frame is formed with a wide opening towards the end where the valve piston is in the 100 % open position and with a narrower opening towards the end where the valve piston is in the closed position.
A receiving node in an optical wireless communications, OWC, network, characterized by the receiving node comprising: a receiving unit, configured to receive a request to send, RTS, frame sent by a sending node by using a first bandwidth, wherein the RTS frame comprises first indication information; a determining unit, configured to determine a second bandwidth based on the first indication information, wherein the second bandwidth is a sending bandwidth used when the sending node sends to-be-sent information and a receiving bandwidth used when the receiving node receives the to-be-sent information; and a sending unit, configured to send a clear to send, CTS, frame to the sending node by using a third bandwidth. a receiving unit, configured to receive a request to send, RTS, frame sent by a sending node by using a first bandwidth, wherein the RTS frame comprises first indication information; a determining unit, configured to determine a second bandwidth based on the first indication information, wherein the second bandwidth is a sending bandwidth used when the sending node sends to-be-sent information and a receiving bandwidth used when the receiving node receives the to-be-sent information; and a sending unit, configured to send a clear to send, CTS, frame to the sending node by using a third bandwidth.
An isolated antibody comprising a heavy chain and a light chain, wherein (a) the heavy chain comprises a heavy chain variable region comprising the three complementary determining regions (CDRs) from the amino acid sequence of SEQ ID NO: 1, wherein HCDR1 comprises SYVMH, HCDR2 comprises YINPYNGGTQYNEKFKG and HCDR3 comprises RTFPYYFDY; and a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:9, wherein the hinge region of the heavy chain constant region comprises at least one amino acid insertion, deletion or substitution; and (b) the light chain comprises a light chain variable region comprising the three complementary determining regions from the amino acid sequence of SEQ ID NO:2, wherein LCDR1 comprises RSSQSILHSNGNTYLE, LCDR2 comprises KVSNRFS and LCDR3 comprises FQGSHAPLT; and a light chain constant region comprising the amino acid sequence of SEQ ID NO: 10 and further comprising at least one amino acid insertion, wherein the antibody binds a carbohydrate epitope on the extracellular domain of a human CD43 and/or human CEA expressed by a nonhematopoietic cancer cell and is capable of inducing apoptosis of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function. (a) the heavy chain comprises a heavy chain variable region comprising the three complementary determining regions (CDRs) from the amino acid sequence of SEQ ID NO: 1, wherein HCDR1 comprises SYVMH, HCDR2 comprises YINPYNGGTQYNEKFKG and HCDR3 comprises RTFPYYFDY; and a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:9, wherein the hinge region of the heavy chain constant region comprises at least one amino acid insertion, deletion or substitution; and (b) the light chain comprises a light chain variable region comprising the three complementary determining regions from the amino acid sequence of SEQ ID NO:2, wherein LCDR1 comprises RSSQSILHSNGNTYLE, LCDR2 comprises KVSNRFS and LCDR3 comprises FQGSHAPLT; and a light chain constant region comprising the amino acid sequence of SEQ ID NO: 10 and further comprising at least one amino acid insertion, wherein the antibody binds a carbohydrate epitope on the extracellular domain of a human CD43 and/or human CEA expressed by a nonhematopoietic cancer cell and is capable of inducing apoptosis of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function.